Good morning. My name is Bailey and I will be your conference operator today. At this time, I would like to welcome everyone to the CTS Corporation Second Quarter 2022 Conference Call. All lines have been placed on mute to prevent background noise. A supplemental slide presentation to accompany the prepared remarks can be found on the company's website. After the speakers' remarks, there will be a question-and-answer session. At this time, I would like to turn over the call to Mr. Kieran O'Sullivan, CEO of CTS Corporation. Mr. O'Sullivan, you may begin your conference.

Thanks, Bailey. Good morning and welcome everyone to our second quarter 2022 earnings call. We delivered another strong quarter. In addition, we finalized the acquisition of Ferroperm Piezoceramics at the end of June, further advancing our diversification strategy. I'm excited to have this talented team join CTS, which will allow us to expand our market opportunities and support a broader range of customers. Sales in the second quarter were $145 million, up approximately 12% compared to the second quarter of 2021. Second quarter adjusted gross margin was 36.1%, down 70 basis points from 36.8% in the second quarter of last year. Adjusted EBITDA margin of 22.4% was up 90 basis points from 21.5% in the same period last year. Second quarter adjusted earnings per diluted share of $0.62 were up almost 20% from $0.52 in the second quarter of 2021. As I already mentioned, during the quarter, we completed the Ferroperm acquisition, and the acquisition is expected to be accretive in 2023. Ashish will take us through the Safe Harbor Statement. Ashish?

I would like to remind our listeners that this conference call contains forward-looking statements. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Additional information regarding these risks and uncertainties is contained in the press release issued today. And more information can be found in the company's SEC filings. To the extent that today's discussion refers to any non-GAAP measures under Regulation G, the required explanations and reconciliation are available in the Investors section of the CTS website. I will now turn the discussion back over to our CEO, Kieran O'Sullivan.

Thank you, Ashish. We had a solid quarter with sales increasing 12% to $145 million versus the second quarter of 2021. Organic sales were up approximately 9% for the quarter. These results underscore our investments in business development as front-end sales enabled us to expand our customer base. The TEWA acquisition added $4 million in sales in the quarter, and the business is performing well. Demand was solid across medical and industrial markets, while defense was softer. Demand for transportation products was impacted by COVID-19 lockdowns in Asia and some OEM production cuts. Our global team continues to execute well and remains committed to both operational excellence initiatives and achieving our long-term goals. Adjusted gross margin for the second quarter was 36.1%, down 70 basis points from 36.8% for the same period last year. We are operating in a very dynamic environment as we continue to be impacted by rising commodity prices, supply chain headwinds, and other macro challenges, which are likely to further pressure margins. However, we continue to partner with our customers to offset or share cost increases, and we expect freight costs to improve in the quarters ahead as Trans-Pacific container volumes to the U.S. return to more normalized pre-pandemic levels. Operationally, we are seeing savings materialize from our restructuring activities. As we move forward, we will continue to evaluate and refine our footprint to optimize our ability to serve our customers, while also enabling us to deliver improved operating leverage. We are also continuing to gain traction with our CTS operating system, with over 90 continuous improvement projects driving incremental performance. Adjusted EBITDA margin was 22.4%, up 90 basis points from 21.5% in the second quarter of 2021. Second quarter adjusted earnings per share of $0.62 were up almost 20% from $0.52 in the same period last year. Improved transportation awards and solid electrification wins drove new business awards in the quarter to $173 million, increasing from the prior quarter. We remain confident in our robust pipeline of opportunities and see good momentum for awards in the coming quarters. By continuing to focus on growth and diversification, we added 6 new customers in the quarter, 4 in industrial and 2 in medical. Additionally, we delivered samples for new products to multiple customers across all end markets. We remain well-positioned in end markets that offer attractive growth opportunities. The quality of our material formulations supported by leading-edge technologies, our deep industry experience, and vertical integration leveraged over several end markets differentiate us from our competitors, helping us deliver long-term value to our customers. As we noted earlier, we completed the acquisition of Ferroperm during the quarter. The company was founded in 1952 and specializes in the design and manufacture of high-performance piezoceramic components for use in complex and demanding medical, industrial, and aerospace applications. This acquisition expands our capabilities and geographic reach of our piezoceramic product portfolio. Ferroperm is recognized for its high quality and innovative technology. Based in Denmark, Ferroperm has established a strong customer base across Europe and in North America. Ferroperm is located within a short distance of our existing ceramics business in Denmark, and we are already evaluating potential plans to consolidate operations into the Ferroperm facility. We are delighted to welcome this talented team to CTS. In the industrial market, demand for our micro actuators for use in industrial printing applications remains solid, driven by online demand. Across temperature sensing, hot and cold applications, we continue to see good momentum with awards for HVAC and strong demand for industrial appliances as consumers return to service industries. We secured wins with two new customers for temperature applications and coffee machines and high-end blender products. Though lower, demand for pool and spa applications remains at reasonable levels. We gained awards in Europe for flow sensing applications and expect revenue from previously shipped samples for combined flow and temperature to begin in 2023. Wins with the RF product line were good in industrial communications and IT applications with wins in 3 regions. We delivered RF samples for a new 5G application for a Japanese customer and added a new Asian customer for a semiconductor equipment application. In Japan, we received an initial order for an industrial welding application. We also secured frequency product wins, and demand was solid for our switch product used in industrial applications, computing, and entertainment equipment. Distribution sales were a little tempered, which we expected after the higher periods we have seen for several successive quarters. Across medical, we are seeing increasing momentum and long-term growth opportunities, building off our first quarter performance. Our targeted business development efforts continue to deliver, resulting in an expanding customer base. We had wins with sleep apnea applications across several customers. We continue to see solid growth across multiple customers for our traditional medical ultrasound products. And we shipped samples to a potential new customer for a cardiac application which removes plaque buildup in blood vessels. We had an additional win for a cataract surgical application that extends through 2023. The sample qualification for handheld medical ultrasound that we discussed last quarter is now in the FDA approval process, which is expected to take between 6 to 9 months to complete. The precision insulin pump application samples previously discussed are expected to gain approval for the first quarter of 2023. Further, we received multiple temperature sensing awards from existing customers, ranging from incubator to critical freezer monitoring and disposable applications, and added 2 new customers, 1 for a temperature cycling application and another for an application using body aesthetics. We also received an award with an existing customer for an application in immunoassay equipment. In aerospace and defense, we continue to remain confident in the long-term prospects for this market driven by the geopolitical environment, as we improve our capabilities with new material formulations. We continue to experience good growth in sonar and guided torpedo applications. And we expect to gain more traction in the European defense market with the addition of Ferroperm. For unmanned underwater vehicles, we continue to develop sample product with a Tier 1 defense customer and expect initial small volume production between late this year and early 2023. In RF filter applications, we experience some near-term softening due to program transitions, but expect to grow with new applications next year. We were also awarded the precision harsh temperature application for a space vehicle and were also awarded extensions on existing timing products. We continue to advance our M&A strategy, which is focused on expanding our geographic reach, adding momentum to our end market profile and increasing the richness of our customer base. As I mentioned earlier, during the quarter, we successfully completed the acquisition of Ferroperm. The addition of Ferroperm strengthens our medical product portfolio by complementing our existing medical imaging products with therapeutic products. Through this acquisition, we also gain industrial and defense product capabilities and new customers. As we have discussed before, our long-term strategic plan is focused on diversifying our end market profile. We plan to achieve this by expanding our range of technologies, products, customers, and geographic reach to accelerate the revenue growth of our non-transportation business, while also strategically growing our transportation business. We believe this strategy continues to bear fruit, as we are seeing the diversification of our business, enhancing our quality of earnings, despite the challenging macroeconomic factors we are facing. The Ferroperm acquisition advances these efforts by supporting the growth of our non-transportation revenue, with the potential of expanding this portion of the business beyond 50% of total revenues. We remain focused on continuing to strengthen our M&A pipeline of opportunities to meet our overall growth target. Our track record of thoughtfully expanding ceramic technology to support diversification, while at the same time leveraging our expertise to build and scale the temperature sensing platform through the acquisitions of QTI, SSI and now TEWA, demonstrates the execution of our strategic plan. Adding technology that will enhance our EV offering also remains a priority. We continue to focus on acquisition targets in the range of up to $50 million a year in sales, but we remain open to the right larger opportunities that will advance our long-term strategy. Our team continues to develop our pipeline of prospects, appropriately deploying capital, in line with our allocation framework is important. And we have maintained a healthy balance sheet, which enables us to maintain flexibility to drive organic growth and make strategic acquisitions while returning capital to shareholders. To that end, in the quarter, we repurchased approximately $7.7 million of CTS stock. In transportation, we continue to perform in an environment where OEMs and Tier 1 suppliers saw sales declines in the quarter. We currently see robust demand in commercial vehicles, which we expect to extend into 2023. On the light vehicle side, while the sales softness remains given the supply side challenges across the industry, our positioning from a product and geographic standpoint has propelled us forward. We remain cautious on light vehicle demand, more from a consumer weakness sentiment than supply disruptions, and view demand trending flat for this year. However, longer-term we see the need for a growth cycle, given the recession level industry volumes of recent years. We continue to focus on strengthening our light vehicle sensor portfolio, especially around EV platforms. Today electric vehicle revenue ranges in the high single-digits as a percentage of our total light vehicle revenue. Our goal is to have greater than 25% of our light vehicle revenue coming from EV platforms by 2025. This goal is supported by our ability to transfer our legacy accelerator module and sensor products to electric and hybrid vehicle applications. This past quarter the level of EV wins as a percentage of transportation wins was up given the lag in some prior quarters as OEMs focus more on supply challenges. We are also developing new products to integrate into existing and future EV architectures such as our eBrake product, which has been prototyped and represents a future growth opportunity similar in magnitude to the existing accelerator module market. In addition, we are getting traction with our current sensor products and are working on potential position sensing products for EV motor application. Our value proposition in transportation has been built on packaging position sensing for safety, critical and harsh environments where our teams have developed deep industry experience. For chassis ride height sensing, we had wins with North American and Chinese OEMs. For passive safety sensors, we had two large Tier 1 wins across Europe and North America, the largest one for an EV application. We had a brake sensor win with a Chinese EV application and a legacy Knock sensor award for a European customer. We also had a second win for our EV current sensing product with a North American Tier 1 customer. Across the accelerator module products, we had multiple wins, 3 with Asian OEMs and additional wins with European and North American OEMs. In addition, 3 of the accelerator awards were for EV platforms. In the quarter, a total of 10 of the awards were for EV applications. Looking ahead and recognizing the macro uncertainty, we currently see good demand in industrial markets and strength in the medical market with some softness in defense as we transition programs. We expect to see continued benefit from our recent acquisitions. Channel inventories are back to more normal levels. Backlogs are flattening or demand currently remains stable. However, we expect market demand may soften throughout the balance of the year. In transportation, the cumulative loss of vehicle builds so far this year has been driven primarily by two factors. COVID-19 had an impact of over 1 million units. And the semiconductor shortage impacted closer to 2 million units or more based on the trend we are seeing, which we feel is likely to end above 3 million units for the year. As I mentioned earlier, we are cautious on older build rates for this year and expect production volumes to grow in the low-single-digits versus the prior year with incremental gains in the years ahead despite a recessionary environment. We expect U.S. light vehicle production to be in the 13 million to 14.5 million unit level. European production has been revised down since the start of the Ukraine war and is now forecasted in the 15 million to 16 million unit range this year. The Chinese market is expected to be flat this year in the 24 million to 25 million unit range. Commercial vehicle demand remains solid. Overall, we feel confident in the long-term prospects for the business. Our teams are creatively navigating the current environment to ensure supply for our customers. We were able to maintain operations this past quarter, while ensuring a safe work environment for our employees during the Asian lockdowns. All our plants remain fully operational. Some industrial and automotive customers continue to confirm demand into 2023. As always, we are monitoring the macro environment very closely. I'm pleased to say in this very challenging environment, our teams are working and adapting with speed and agility to support our customers. In terms of the financial outlook for the full year 2022, our updated guidance, including the Ferroperm acquisition, is for sales to be in the range of $570 million to $600 million, up from the previous range of $550 million to $580 million. Adjusted earnings per share are now expected to be in the range of $2.40 to $2.55 compared to the previous range of $2.20 to $2.45. Now I'll turn it over to Ashish, who will walk us through the financial results in more detail.

Thank you, Kieran. Second quarter sales were $145 million, up 11.9% compared to the second quarter of 2021 and down 2% sequentially from the first quarter of 2022. Foreign currency exchange rates impacted revenue unfavorably by approximately $2.2 million. Sales to non-transportation end markets increased 21.1% year-over-year, supported by another quarter of double-digit growth in the industrial and medical end markets. Excluding sales from TEWA acquisition, sales to non-transportation end markets were up 14.1% year-over-year. Sales to transportation customers increased 4.4% compared to the second quarter of 2021. We have continued to see momentum in our smart actuator products, which primarily go into commercial vehicle applications. Sales to the transportation end market decreased 5.6% sequentially due to lower market volumes caused by supply constraints and COVID-related shutdowns. Our adjusted gross margin was 36.1% in the quarter, down 70 basis points compared to the second quarter of 2021 and down 110 basis points compared to the first quarter of 2022. Inflationary factors and supply chain headwinds pressured margins during the quarter, which we were able to partially offset through pricing and operational improvements across our organization. Foreign currency exchange rates also impacted gross margin unfavorably by approximately 0.5 percentage point. We have realized $0.19 of savings to date from our previously announced restructuring program. As previously communicated, we are on target to achieve the lower end of the $0.22 to $0.26 of savings. However, some of these projects will extend into 2023 as we balance growth with the completion of the projects. We reported earnings of $0.39 per diluted share for the second quarter. Adjusted earnings for the second quarter were $0.62 per diluted share compared to $0.52 per diluted share for the same period last year and $0.67 per diluted share in the prior quarter. Moving on to cash generation and the balance sheet, we generated $16.1 million in operating cash flow for the second quarter of 2022. Cash flow was impacted by the movement in foreign currency exchange rates. Controllable working capital was at 17.7%, higher than the first quarter primarily due to the addition of the balance sheet from our Ferroperm acquisition. We remain focused on ongoing cash generation and a healthy balance sheet that have enabled our focus on organic growth and strategic acquisitions. We repurchased approximately 216,000 shares of CTS stock during the quarter totaling $7.7 million. In total, we returned approximately $9 million to the shareholders in the second quarter and $14 million year-to-date through dividends and buybacks. We ended the second quarter with a cash balance of $98.7 million as of June 30, 2022 and our long-term debt balance was $91 million. The debt to capitalization ratio was at 15.8% at the end of the second quarter compared to 9.9% at the end of the prior year period. During the second quarter, we funded our Ferroperm acquisition partly with cash outside the U.S. and the balance through our existing credit facility. Our leverage and cash position allow us to continue evaluating further strategic acquisitions. This concludes our prepared comments. We would like to open the line for questions at this time.

To start, I wanted to ask about the updated guidance. Is there any way you could ballpark how much of the increase was driven by the acquisition versus upside in the business from an organic basis?

So Justin, in terms of sales, we have talked about the acquisition delivering in the low to mid $20 million range. So that'll give you a rough idea of how much to expect in the second half of the year, $10 million, $11 million is how we are thinking about it. And the EPS, we are not counting on much accretion at this point. Most of it we are expecting in 2023.

Got it. So that EPS raise at the midpoint I think was around $0.15. Is there a little bit more color you can provide on the key drivers to that upside?

So the biggest one is our continued improved confidence in the revenue expectation from our core business. And we have also been continuing to work on offsetting the cost pressures with pricing and operational improvements like we talked about. So those are what are contributing to our improved confidence around the EPS numbers.

Got it. And last one on the guidance. Looking at the implied EPS guidance for the second half of the year, is there anything you can share on your expectation for the quarterly cadence of EPS? Do you feel like it will be relatively even in Q3 and Q4 or is there anything or any reason to expect one quarter to be stronger than the other?

I think the best way to answer that is, as we see at the moment, we are off to a reasonable start in Q3. We don't have the same level of visibility yet into Q4 is probably the best way to answer that, Justin.

Okay. Got it. And last question for me. Obviously, there are a lot more headlines around the economy and economic concerns. If I kind of reflect back on when the pandemic initially hit in 2020, I felt like you moved pretty quickly to adjust the cost structure lower. If some of the recession headlines become a reality, can you talk about how quickly you can adjust the cost structure moving into next year? And maybe just from a high level, I'm curious what kind of economic environment you're planning for as we look into 2023?

So Justin, two points in that. And in our prepared remarks, we said we expect some softness in the second half of the year. Obviously, the degree of that is not clear yet. And if you look back to the COVID period when we had to respond to a pretty down market where we saw huge drops even in transportation, we remain positive. We adapted our cost structure pretty much within a quarter and had things moving. And we tried to do that very thoughtfully, so that we're improving the long-term prospects of the business as well.

I want to start with, you had previously voiced some concerns about supply chain issues, really calling it a whack-a-mole kind of a situation? Can you give us update of the supply chain issues facing the company? Are they behind you at this point? Any kind of color would be appreciated.

Yes, Jon, I would say for the most part in the non-transportation markets, we're doing pretty well. That doesn't mean we don't have issues but we're still managing through that pretty well. On the transportation side, it has improved and is improving. And we still have one or two watches on the semiconductor side. But several have improved. So we expect a little better second half. I think more of our concern in transportation as we look forward beyond supply chain is just where the consumer is with inflation and will that bring any softness to demand as well.

And regarding Ferroperm, can you talk a little bit about that piezo technology that they bought? Is it materially different than what you were doing? Or is it a scenario where you just access to new markets and new customers was the bigger driver of the acquisition?

The technology Jon is very similar to what we're doing at the moment. But it allows us to scale with new products and new customers. As an example, we said therapeutics, so we're in the pacemakers. We're into skin care, other applications in that area. But we really like it. And it also gives us capability in industrial applications and aerospace and defense for high temp applications.

Jon, they have a good technology team. They have good powder formulations, which will add to our portfolio of ceramic compounds that we can offer that are suitable for different applications. So that's really what we gain out of the acquisition in addition to depth in the European markets.

And Jon, we expect it to help us penetrate the defense markets in Europe even more.

When discussing the potential for non-transportation related businesses to exceed the 50% threshold, I am specifically comparing the temperature sensing portfolio to the piezo portfolio. Which of these is likely to be the main factor in achieving more than 50%?

Jon, both product areas are pretty important to us and we're moving on in several end markets with each of those. And I'd tell you, if we look today, we're probably closer to a 48-52 split, so that's before Ferroperm. So we see ourselves crossing that bridge in the future.

Got it. And just one last here. I think, Kieran, I heard you say that the inventory levels at the customer level are close to equilibrium now. Is that the case? There's no inventory stocking going on, and people are worried about supply chain issues that you need to worry about?

Jon when I was talking about inventory, it was more for the distribution side of the business, which is now approximately 10% of our sales, and just saying it's getting back to more normal levels.

If you consider the broader perspective, is the balance of your customer base at inventory equilibrium?

Transportation side, we're not seeing any inventory issues and in the other markets we're doing pretty well. No big issues to flag at this point in time.

I wanted to follow-up on some of Justin's questions from earlier. The guidance sort of implies a flat second half versus the first half despite tailwind from Ferroperm and TEWA. I understand you pointed us to some weakness. But could you walk us through some of the assumptions that are baked into the guidance? In particular, I'm asking because bookings were again above $170 million this quarter. So it doesn't seem like you're seeing a material slowdown in demand yet, but I was wondering where you're taking a potentially more conservative approach?

Yes. Josh, there are several parts to your question. First of all, the bookings, Kieran pointed out in his call that a lot of the strength in the booking compared to the first quarter came from the transportation market where we don't recognize sales from those bookings for a period of time, typically two to three years. The demand environment, we are expecting stable compared to Q2, Q1 for the transportation with potential to increase. But again, there's that question mark of does the consumer demand start softening because of higher interest rates? And in the rest of the end markets, we are concerned about potential softening as we go towards the end of the year. So that's sort of the backdrop that we are looking at in terms of end market dynamics.

And then on the inventory line, inventory picked up sequentially. But you also closed Ferroperm on June 30th, I believe. Is there a way to back out how much of the inventory increase was due to just closing the deal and the inventory step up versus what happened organically with prior CTS?

Yes, so our working capital would be about 1.5 points lower without the Ferroperm acquisition.

Thank you. I noticed in the presentation that you mentioned a target of over 25% of transport coming from EVs by 2025, and that longer-term, around 25% of your serviceable available market will be from EVs. Are there any benchmarks available to gauge how that business is performing today, particularly for applications like current sensors and eBrakes, or should we expect it to become significant more toward the latter half of the decade? Thanks, and congratulations again.

Great. Thanks. Just on that question, well, some of the wins in EV and some of the growth in EV today is from legacy product. And we mentioned in the prepared remarks that on the EV side our first wins on new product, so with current sensing where we have had two wins. So you are going to see that grow incrementally. And obviously past 2025, we'd expect that to accelerate.

On the eBrake product, Josh, we would expect revenue only in the second half of the decade beyond 2025.

Yes. My first question is on Ferroperm. I think you indicated that accretion will be in 2023. May I inquire like how much operating expense dollars come from Ferroperm, let's say, in the second half for '22? And given your comment that accretions will be in 2023, does that imply that the operating profitability is somewhat comparable to your corporate CTS level?

So Hendi, in the initial period of the acquisition, we will be incurring some incremental expenses. So, without going into the details of operating expense levels, the overall profitability of the business will be accretive to CTS. So the gross margins will help us from a mix standpoint. And as we work through the initial integration period, then that's when we start expecting accretion as we get towards the end of this year, early next year.

And Hendi, the quality of the earnings is something we like about the business.

Okay. And then I think on the more optimism or more optimistic side, may I know what the top end of the sales guidance imply, Kieran?

On the high end, we anticipate either no softening in the other markets or only very slight softening, with transportation remaining strong or experiencing slight growth. Conversely, on the low end, we expect softness in the non-transportation markets while transportation remains stable. This summarizes our outlook on the guidance range.

And then, with regard to the goal of like more than 25% of revenue in light vehicle sensors come from EV, should we expect the EV customer base by 2025 represents your existing customer base? Or should we expect it may look different than your legacy customer base, Kieran?

It will have some legacy, but also some new customers. And actually we have been adding some new customers in that space already, Hendi. So it'll definitely change.

Thank you for your participation. You may now disconnect your lines.

Thanks, Bailey. And thank you again for joining us today. I also want to thank our global teams for their dedicated efforts in driving strong execution and operational efficiency. I'm confident that our diversification strategy, bolstered by our recent M&A activities and the breadth of our geographic footprint, will position us for profitable growth while navigating the macro uncertainty we all face. I'd like to reiterate that CTS is well positioned for future growth. We have a strong team aligned around common goals that continues to advance the business for long-term value creation for our shareholders. Thank you. This concludes our call.